Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline data to regulatory filing in 70 days. 

With bad news in the headlines at home and globally, and a seesawing public market capable of wiping years of value from company books almost overnight, it can be difficult to remain focused on the bread-and-butter tasks that keep a company afloat.

An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T therapies on the cover of Time magazine.

As news reporter covering the biopharmaceutical industry in the early aughts, the summer months could present a different kind of challenge.

Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.

Is it time to stop worrying and love the drugs? Psychedelic medicines promise a radical solution to endemic mental health conditions, but caution is needed to cross the finish line.

MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate for PTSD.

A Q&A with Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, on the $7.2 billion acquisition, integration, and future of cannabis drug pioneer GW Pharmaceuticals.

Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good story is the first step.